CA3240907A1 - Inhibitors of met kinase - Google Patents
Inhibitors of met kinase Download PDFInfo
- Publication number
- CA3240907A1 CA3240907A1 CA3240907A CA3240907A CA3240907A1 CA 3240907 A1 CA3240907 A1 CA 3240907A1 CA 3240907 A CA3240907 A CA 3240907A CA 3240907 A CA3240907 A CA 3240907A CA 3240907 A1 CA3240907 A1 CA 3240907A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- compound
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290291P | 2021-12-16 | 2021-12-16 | |
| US63/290,291 | 2021-12-16 | ||
| US202263301267P | 2022-01-20 | 2022-01-20 | |
| US63/301,267 | 2022-01-20 | ||
| US202263380049P | 2022-10-18 | 2022-10-18 | |
| US63/380,049 | 2022-10-18 | ||
| US202263386647P | 2022-12-08 | 2022-12-08 | |
| US63/386,647 | 2022-12-08 | ||
| PCT/US2022/081504 WO2023114809A1 (en) | 2021-12-16 | 2022-12-14 | Inhibitors of met kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3240907A1 true CA3240907A1 (en) | 2023-06-22 |
Family
ID=85199244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3240907A Pending CA3240907A1 (en) | 2021-12-16 | 2022-12-14 | Inhibitors of met kinase |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11753395B2 (https=) |
| EP (1) | EP4448510A1 (https=) |
| JP (1) | JP2025500917A (https=) |
| KR (1) | KR20240121851A (https=) |
| AU (1) | AU2022413540A1 (https=) |
| CA (1) | CA3240907A1 (https=) |
| CL (1) | CL2024001756A1 (https=) |
| CO (1) | CO2024009144A2 (https=) |
| IL (1) | IL313548A (https=) |
| MX (1) | MX2024007444A (https=) |
| TW (1) | TW202333709A (https=) |
| WO (1) | WO2023114809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023114809A1 (en) | 2021-12-16 | 2023-06-22 | Kinnate Biopharma Inc. | Inhibitors of met kinase |
| CN121038792A (zh) * | 2023-04-17 | 2025-11-28 | 赛琳治疗公司 | 用met激酶抑制剂治疗癌症 |
| WO2024259060A1 (en) * | 2023-06-16 | 2024-12-19 | Kinnate Biopharma Inc. | Inhibitors of met kinase |
| WO2025096463A1 (en) * | 2023-10-30 | 2025-05-08 | Vibliome Therapeutics, Llc | Plk4 modulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| EP0860433B1 (en) | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| JO2785B1 (en) | 2003-05-27 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinazoline derivatives |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US20070155746A1 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases |
| JP2009539878A (ja) | 2006-06-08 | 2009-11-19 | アレイ バイオファーマ、インコーポレイテッド | キノリン化合物および使用方法 |
| US20090049035A1 (en) | 2007-08-14 | 2009-02-19 | International Business Machines Corporation | System and method for indexing type-annotated web documents |
| JP2010126530A (ja) | 2008-12-01 | 2010-06-10 | Takeda Chem Ind Ltd | 縮合複素環誘導体およびその用途 |
| CN102573994B (zh) | 2009-08-06 | 2015-06-24 | 默克专利有限公司 | 双环脲化合物 |
| EP2423208A1 (en) | 2010-08-28 | 2012-02-29 | Lead Discovery Center GmbH | Pharmaceutically active compounds as Axl inhibitors |
| CN102827186A (zh) | 2011-06-16 | 2012-12-19 | 中国科学院上海药物研究所 | 一类吡啶并五元杂环衍生物及其制备方法和用途 |
| JP2015507606A (ja) | 2011-11-22 | 2015-03-12 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌および抗増殖作用を示すピリドンアミドおよび類似体 |
| WO2013180949A1 (en) * | 2012-05-27 | 2013-12-05 | Ning Xi | Substituted quinoline compounds and methods of use |
| CN103508961B (zh) | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| EP3003315B1 (en) | 2013-06-06 | 2018-01-17 | Lead Discovery Center GmbH | A quinoline inhibitor of the macrophage stimulating 1 receptor mst1r |
| KR101505783B1 (ko) | 2014-08-01 | 2015-03-25 | 씨제이헬스케어 주식회사 | 신규한 피롤로피리디닐옥시페닐아미드 유도체 및 이의 용도 |
| SG11201707638UA (en) | 2015-04-14 | 2017-10-30 | Qurient Co Ltd | Quinoline derivatives as tam rtk inhibitors |
| CN105153026B (zh) | 2015-08-21 | 2018-02-02 | 江西科技师范大学 | 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用 |
| CN105732616B (zh) | 2016-01-08 | 2018-07-27 | 江西科技师范大学 | 含联芳基酰胺结构的吡咯并吡啶类化合物及其制备方法和应用 |
| CN109896997A (zh) | 2017-12-08 | 2019-06-18 | 中国药科大学 | N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途 |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| CN111196814B (zh) | 2018-11-19 | 2022-12-06 | 北京赛特明强医药科技有限公司 | 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 |
| JP2022551422A (ja) * | 2019-09-26 | 2022-12-09 | エグゼリクシス， インコーポレイテッド | ピリドン化合物およびタンパク質キナーゼの調節における使用の方法 |
| WO2023114809A1 (en) | 2021-12-16 | 2023-06-22 | Kinnate Biopharma Inc. | Inhibitors of met kinase |
-
2022
- 2022-12-14 WO PCT/US2022/081504 patent/WO2023114809A1/en not_active Ceased
- 2022-12-14 MX MX2024007444A patent/MX2024007444A/es unknown
- 2022-12-14 JP JP2024536124A patent/JP2025500917A/ja active Pending
- 2022-12-14 CA CA3240907A patent/CA3240907A1/en active Pending
- 2022-12-14 TW TW111148006A patent/TW202333709A/zh unknown
- 2022-12-14 EP EP22854688.3A patent/EP4448510A1/en active Pending
- 2022-12-14 US US18/066,056 patent/US11753395B2/en active Active
- 2022-12-14 IL IL313548A patent/IL313548A/en unknown
- 2022-12-14 AU AU2022413540A patent/AU2022413540A1/en active Pending
- 2022-12-14 KR KR1020247023755A patent/KR20240121851A/ko active Pending
-
2023
- 2023-06-26 US US18/341,503 patent/US12595245B2/en active Active
-
2024
- 2024-06-13 CL CL2024001756A patent/CL2024001756A1/es unknown
- 2024-07-11 CO CONC2024/0009144A patent/CO2024009144A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022413540A1 (en) | 2024-07-18 |
| US20230219929A1 (en) | 2023-07-13 |
| MX2024007444A (es) | 2024-09-02 |
| IL313548A (en) | 2024-08-01 |
| CL2024001756A1 (es) | 2024-11-29 |
| CO2024009144A2 (es) | 2024-08-08 |
| JP2025500917A (ja) | 2025-01-15 |
| US11753395B2 (en) | 2023-09-12 |
| WO2023114809A1 (en) | 2023-06-22 |
| TW202333709A (zh) | 2023-09-01 |
| EP4448510A1 (en) | 2024-10-23 |
| US20240067626A1 (en) | 2024-02-29 |
| US12595245B2 (en) | 2026-04-07 |
| KR20240121851A (ko) | 2024-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11884680B2 (en) | Bromodomain inhibitors | |
| JP7026196B2 (ja) | Ｒｅｔの阻害剤 | |
| CA3240907A1 (en) | Inhibitors of met kinase | |
| AU2023207390A1 (en) | Six-membered cyclothiazole compound and use thereof | |
| EP3405192B1 (en) | Bruton's tyrosine kinase inhibitors | |
| CA3138300A1 (en) | Inhibitors of raf kinases | |
| WO2022081469A1 (en) | Inhibitors of raf kinases | |
| WO2013100672A1 (ko) | 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체 | |
| US12122800B2 (en) | Inhibitors of MEK kinase | |
| US20250145599A1 (en) | Certain chemical entities, compositions, and methods | |
| US12338262B2 (en) | Modulators of TNF-alpha activity | |
| CN118742542A (zh) | Met激酶的抑制剂 | |
| WO2024259060A1 (en) | Inhibitors of met kinase | |
| WO2026015385A1 (en) | Substituted pyrido[4,3-d]pyrimidines as kras modulators | |
| HK1241705B (zh) | 治疗性抑制化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250602 |